CLINICAL TRIALS ARTICLES

  • "Raiders Of The Lost Codon:" Alltrna On Evolving "Ancient" tRNA Into Therapeutics

    Here, in part one of this two-part article, we identify how tRNA stands apart from other RNA modalities and gene therapies, as well as how this molecule’s unique “skill set” is guiding the company’s future clinical strategy.

  • Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics

    Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.

  • Cultivating A Thriving mRNA Ecosystem: Key Initiatives & Future Directions

    Overall, I felt that the following initiatives/talking points were demonstrative of the types of creativity and symbiosis that we will need much more of in the near and long-term to foster a healthy and fruitful RNA ecosystem. 

  • From Promise To Precision: Defining The Therapeutic Niche for mRNA

    CureVac CEO Alexander Zehnder shares his thoughts/visions on how mRNA neoantigen vaccines could become even more revolutionary for patient populations in the future. Though it may be early days, this conversation is a great case study for how RNA companies are striving to keep both scientific and commercial market opportunities top of mind from the earliest days of development.

  • The Marriage of Science & Strategy: Identifying mRNA Therapeutics' Value Propositions

    Though it’s not a question we can answer fully yet, in the first of this two-part article, CureVac CEO Alexander Zehnder starts us down the path of answering a critical question about our RNA therapies: In what ways can and should our mRNA products add value to our patients’ lives?

  • Top 5 mRNA/RNA Developments of 2024 (Part 1)

    In the past few weeks, I’ve shared two articles outlining several RNA executives’ thoughts on advancements from 2024, as well as the challenges facing us in 2025. But why stop there? Below in the first of this two-part article, I share the first two of my five overarching observations from 2024.

CLINICAL TRIALS VIDEOS

This presentation aims to equip sponsors, researchers, and stakeholders with the tools to enhance trial resilience and ensure continuity in today’s unpredictable global landscape.

This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.

In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research.

Need help unravelling the complexity of CGTx development? Four experts explain Precision ADVANCE’s unique approach. Spend 50 seconds with Anshul Mangal, Deb Phippard, Megan Liles, and Philip Cyr.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS